EverPoint Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

EverPoint Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.6M	Sell	800,000 -275,000	-26%	-$4.7M	0.2%	135
2016 Q3	$25.5M	Buy	+1,075,000	New	+$28.9M	0.46%	56
2015 Q4	–	Sell	-400,000	Closed	-$14.1M	–	581
2015 Q3	$14.1M	Sell	400,000 -110,000	-22%	-$4.96M	0.37%	73
2015 Q2	$23.4M	Buy	+510,000	New	+$24.2M	0.43%	54

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EverPoint Asset Management's IPXL Position: Q4 2016 in Review

EverPoint Asset Management reduced its Impax Laboratories, Inc. (IPXL) stake by 26% in Q4 2016, selling an estimated $4.7M and leaving 800,000 shares worth $10.6M. The position accounts for 0.2% of the portfolio, ranked #135.

EverPoint Asset Management first reported a position in IPXL in Q2 2015 and has held it in 4 quarters since. The position peaked at $25.5M in Q3 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

EverPoint Asset Management held 800,000 shares of Impax Laboratories, Inc. worth $10.6M as of Q4 2016.
EverPoint Asset Management sold 275,000 Impax Laboratories, Inc. shares in Q4 2016, an estimated $4.7M.
Impax Laboratories, Inc. made up 0.2% of EverPoint Asset Management's portfolio in Q4 2016, its #135 holding.
EverPoint Asset Management first reported a position in Impax Laboratories, Inc. in Q2 2015 and has held it in 4 quarters since.
EverPoint Asset Management's Impax Laboratories, Inc. position peaked at $25.5M in Q3 2016.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.